1. Ikemura N, Taminishi S, Inaba T, Arimori T, Motooka D, Katoh K, Kirita Y, Higuchi Y, Li S, Suzuki T, Itoh Y, Ozaki Y, Nakamura S, Matoba S, Standley DM, Okamoto T (corresponding author), Takagi J, Hoshino A, An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci Transl Med, (In press)
2. Tanaka T, Saito A, Suzuki T, Miyamoto Y, Takayama K, Okamoto T, Moriishi K. Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. Antiviral Res. 2022 Mar;199:105268. doi:10.1016/j.antiviral.2022.105268
3. Miyamoto Y, Itoh Y, Suzuki T, Tanaka T, Sakai Y, Koido M, Hata C, Wang CX, Otani M, Moriishi K, Tachibana T, Kamatani Y, Yoneda Y, Okamoto T, Oka M. SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication. Commun. Biol. (accepted in principle)
4. Tsuji S, Minami S, Hashimoto R, Konishi Y, Suzuki T, Kondo T, Sasai M, Torii S, Ono C, Shichinohe S, Sato S, Wakita M, Okumura S, Nakano S, Matsudaira T, Matsumoto T, Kawamoto S, Yamamoto M, Watanabe T, Matsuura Y, Takayama K, Kobayashi T, Okamoto T, Hara E. SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response. Nat Aging. 2022 Jan 25;2:115-124. doi.org/10.1038/s43587-022-00170-7
5. Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y, Ohgitani E, Mazda O, Motooka D, Nakamura S, Sakai Y, Itoh Y, Sugihara F, Matsuura Y, Matoba S, Okamoto T, Takagi J, Hoshino A. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021 Jun 21;12(1):3802. doi: 10.1038/s41467-021-24013-y
6. Tsuji K, Yamada S, Hirai K, Asakura H, Kanda Y. Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing. J Toxicol Sci. 2021, 46(9), 425-435. doi: 10.2131/jts.46.425
7. Yanagida S, Satsuka A, Hayashi S, Ono A, Kanda Y. Comprehensive cardiotoxicity assessment of COVID-19 treatments using human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2021, 183(1), 227-239. doi: 10.1093/toxsci/kfab079
8. 山田茂,諫田泰成, ヒトiPS細胞技術を活用したCOVID-19治療薬の開発. 日本薬理学雑誌. 2022, 157, 124-127, doi: 10.1254/fpj.21078
9. RNAウイルスの新規リバースジェネティクス法とその応用, 鈴木達也、齊藤暁, 日本薬理学雑誌 157(2) 134-138 2022年